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Various mediators of inflammation have been suggested as being important in the pathogenesis of asthma. 
These include histamine, acetylcholine, bradykinin, adenosine, prostaglandins D, and F,a, thromboxane A,, 
leukotrienes, PAF and, more recently, various cytokines. Intervention in the action of these mediators is 
proposed to offer therapeutic benefit, and recent advances in drug therapy have centred on two main 
approaches. Specific and potent leukotriene antagonists and inhibitors of leukotriene biosynthesis have 
emerged, and their effects against allergen challenge, cold-air- and exercise-induced bronchospasm and 
aspirin-sensitive asthma have been evaluated. A small number of studies have also been conducted in clinical 
asthma, with both acute and long-term (up to 20 weeks) efficacy studies being reported. A considerable degree 
of inter-individual variation is seen in the degree of protection afforded by leukotriene intervention. The extent 
to which inhibiting one set of inflammatory mediators can be expected to attenuate the asthmatic response can 
be questioned. As yet, there is no way of distinguishing leukotriene-related asthma from other types. It is likely, 
however, that leukotriene intervention may be useful in some patients with specific forms of the disease; for 
example, aspirin-sensitive asthma. Leukotriene intervention is unlikely to replace inhaled corticosteroids in the 
treatment of asthma, and its position in the guidelines for the management of asthma remain unclear thus far. 
Introduction 
Asthma is now well established as involving 
chronic airway inflammation. Inflammation may be 
considered in terms of inter-related acute and chronic 
processes (1). Acute inflammation develops rapidly, 
involves cell activation, mediator release, vascular 
permeability changes and inflammatory cell recruit- 
ment into tissues, and is reversible. Exposure of 
sensitized individuals to a specific allergen evokes an 
immediate response, thought to be primarily induced 
by bronchospastic mediators such as histamine, pros- 
taglandin D, and leukotriene C, from IgE-triggered 
mast cells. This is followed in many cases, after a few 
hours, by a late response. This appears to result from 
tissue oedema and the activation, migration and 
recruitment of inflammatory cells leading to further 
mediator generation (1,2). Chronic inflammation 
involves increased tissue residency of intlammatory 
cells, a further spectrum of mediator release, and 
cellular damage and remodelling. It progresses more 
slowly and is potentially less reversible. 
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Bronchoscopic biopsy evidence establishes that 
inflammatory cells, particularly eosinophils and 
lymphocytes, are present in the bronchial mucosa (2) 
and that inflammatory cell products and plasma 
proteins are found in the bronchial lumen (3). The 
use of agents which suppress the inflammatory pro- 
cess has become an integral part of asthma treatment. 
Corticosteroids are established as highly effective 
therapy, related to their potent inhibitory activity 
against both acute and chronic inflammatory 
processes. 
The recent development of potent leukotriene 
antagonists and synthesis inhibitors allows an evalu- 
ation of the importance of this class of mediators in 
asthmatic inflammatory processes. This review will 
discuss and assess the evidence regarding a role for 
leukotriene intervention in asthma, how asthmatic 
responses are affected and how these effects compare 
with current drug treatments. 
Biological Properties of Leukotrienes 
In vitro, on human isolated bronchus preparations, 
leukotriene C, (LTC,) and LTD, are at least 1000 
times more potent than histamine in causing smooth 
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Fig. I Leukotrienes biosynthesis simplified scheme. Enzymes are in boxes. 
muscle contraction, with a long duration of action 
(4). Both large and small airways of normal and 
asthmatic subjects are constricted by cysteinyl leuko- 
trienes in vivo (5-8). However, the concentration 
required to achieve a given bronchoconstrictor 
response varies considerably between individuals (7). 
Although the airways of asthmatic patients in vivo are 
more responsive to LTC!,, LTD, and LTE, than 
those of non-asthmatics (8) the degree of hyper- 
responsiveness is not as great as that seen with 
histamine or methacholine. The reason for this rela- 
tive decrease in hyper-responsiveness of asthmatics to 
inhaled leukotrienes is not clear. 
In addition to their effects on smooth muscle, 
leukotrienes increase mucus production (9), attenuate 
ciliary function (10) and promote microvascular per- 
meability and oedema formation (1 l), all properties 
which may be relevant to the pathogenesis of asthma. 
Leukotriene Biosynthesis and Metabolism 
Leukotrienes C,, D, and E, account for the bio- 
logical activity formerly known as slow-reacting 
substance of anaphylaxis. They are produced by 
neutrophils, macrophages, basinophils, eosinophils 
and monocytes following immunological challenge 
or non-specific stimulation when phospholipase A, 
is activated and cleaves arachidonic acid from the 
membrane phospholipids (Fig. 1). The resulting free 
arachidonic acid is then metabolized by two major 
pathways. One pathway leads to the production 
of prostanoids and thromboxane via the cyclo- 
oxygenase enzyme system. The other pathway leads 
to the formation of leukotriene A, via the action 
of Slipoxygenase. Following cell activation, 5- 
lipoxygenase is translocated from a site within the cell 
to the nuclear envelope where a novel activating 
protein, 5-lipoxygenase-activating protein (FLAP), is 
localized. FLAP is postulated to facilitate the transfer 
of arachidonic acid from the membrane phospho- 
lipase to 5-lipoxygenase. Proton abstraction and 
oxygenation of arachidonic acid by 5-lipoxygenase 
produces the intermediate SHPETE, with a second 
proton abstraction and a dehydration step producing 
leukotriene A4. Leukotriene A, is unstable and 
may either by hydroxylated to form LKB,, or gluta- 
thione is incorporated in which case LTC, is formed. 
Cleavage of glutamic acid in LTC, leads to LTD, 
and then glycine is removed by a dipeptidase to 
form LTE,. 
Leukotriene Receptors 
There are two classes of receptor for leukotrienes 
(Fig. 2); those for LTB,, termed BLT receptors, and 
those for cysteinyl leukotrienes, CysLT receptors. 
Two broad sub-groups of CysLT receptors have been 
recognized. Those blocked by known antagonists are 
termed CysLT, receptors, and those that are resistant 
to blockade are known as CysLT, receptors. In 
human airway smooth muscle, LTC,, LTD, and 
LTE, all activate CysLT, receptors (12). 
Leukotrienes and Asthma 
Raised levels of leukotrienes are detected in 
tissues and fluids from asthmatic patients compared 
with normal individuals (13,14). In particular, LTE, 
is found in bronchoalveolar lavage fluid of asth- 
matic volunteers (15) but not in healthy subjects. 
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Leukotriene E, is a stable end-product of leukotriene 
generation and its detection is used as a marker of 
systemic leukotriene release. Increased urinary levels 
of LTE, are found in many but not all patients 
presenting with acute asthma (16). 
However, no correlation is found between clinical 
asthma severity, as measured by the degree of airflow 
obstruction or bronchial hyper-responsiveness, and 
the level of LTE, in the urine of stable asthmatic 
subjects (17). It has been suggested that subjects with 
rapid and substantial reversal of airway obstruction 
in response to inhaled bronchodilators may exhibit 
the greatest excretion of urinary LTE,. This implies 
that in such subjects, a major mechanism of airflow 
obstruction may be leukotriene-mediated broncho- 
spasm. By contrast, in non-bronchodilator-responsive 
patients, airway oedema, mucus and inflammatory- 
cell mediators may be more relevant factors in 
causing airway obstruction. 
Increased recovery of leukotrienes is also observed 
from both the lung and nose of sensitized subjects 
following allergen exposure, and in aspirin-induced 
asthma, although there is a wide range in the quantity 
of leukotrienes produced under these conditions. 
Urinary LTE, has not been found to be increased 
in adult asthmatics with exercise-induced broncho- 
constriction (EIB) (18) despite the fact that pharma- 
cological studies do suggest a role for leukotrienes 
in EIB (19,20). Leukotrienes also appear to modify 
airway responses to other spasmogens, and may 
therefore play a role in non-specific bronchial 
hyper-reactivity (21). 
However, the hypothesis that even complete abla- 
tion of a pathway involving a single set of mediators, 
leaving other components of the inflammatory pro- 
Trigger factors including physical 
stimuli, allergens, aspirin etc. 
i 
Mediator producing cell(s) 
Histamine, leukotrienes, prostaglandins, PAF etc. 
I 4 Inflammatory processes involved in asthma 
Fig. 3 Leukotriene involvement in asthma. 
cess unaffected, will have a central role in asthma 
therapy requires testing (Fig. 3). 
Anti-leukotriene Drugs 
Two general approaches for intervention in leuko- 
triene pathways have been investigated: (1) blocking 
the actions of leukotrienes at the receptor level (Fig. 
2); and (2) inhibition of biosynthesis (Fig. 1). 
RECEPTOR ANTAGONISTS 
All current leukotriene antagonists act at CysLT, 
receptors, no specific blockers of CysLT, receptors 
have yet been identified. Initial studies with leuko- 
triene antagonists in asthma were disappointing 
because of very low potency and lack of efficacy of 
early compounds. Newer antagonists, as exemplified 
by zafirlukast (ICI-204219, Accolate Zeneca), MK- 
679/MK-571 and MK-476, SKB-104353, ONO-1078, 
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RG-12525 and BAY-X7195 have shown high 
potency and selectivity. In vivo experiments have 
shown the leukotriene antagonists to be effective, to 
varying degrees, in inhibiting the response to inhaled 
LTD, causing a shift to the right of the LTD, 
concentration-response curve. It is unclear to what 
extent the differences in effect are due to differences in 
the potency of the antagonists. 
BIOSYNTHESIS INHIBITORS 
An alternative approach to receptor blockade is 
inhibition of the enzymatic cascade leading to leuko- 
triene production. This has the potential advantage 
of reducing leukotriene B,, C,, D, and E, production 
and 5-HETE (Fig. 2). There have been two ap- 
proaches to the inhibition of 5-lipoxygenase; direct 
inhibition of enzyme activity and antagonism of 
FLAP. As with the leukotriene antagonists, initial 
studies with 5-lipoxygenase inhibitors were dis- 
appointing. Results with more recent compounds 
exemplified by zileuton (A-64077, Leutrol Abbott 
Laboratories) and D-21 38 have been more encourag- 
ing. MK-886, MK-591 and BAY-X1005 have no 
direct activity on 5-lipoxygenase but prevent the 
translocation of the enzyme to the nuclear membrane. 
Clinical Experience with Anti-leukotriene Drugs 
RECEPTOR ANTAGONISTS 
The efficacy of leukotriene receptor antagonists in 
blocking the development of leukotriene-induced 
bronchoconstriction is well documented. A single 
oral dose of zafirlukast 40 mg in normal subjects has 
been shown to produce a large shift of >lOO-fold of 
the LTD, dose-response curve at 2 h post-dose, 
reducing to nine-fold at 12 h (22). The protection 
afforded correlated well with blood levels of zafirlu- 
kast across time points, but there was significant 
variation between subjects with respect to blood 
levels and efficacy. Pharmacokinetic data would be 
expected to predict pharmacodynamic results in 
studies of zafirlukast in asthmatic patients. However, 
the exact nature of the variability is not clear. The 
possibility remains that subject variability occurs 
irrespective of blood levels and is due to differences in 
the relative importance of the leukotriene pathway in 
different subjects. Zafirlukast had no effect on base- 
line pulmonary function in this study (22). In a study 
in mild asthmatics, a progressive shift in the LTD, 
dose-response relationship was demonstrated, with a 
mean magnitude of lo-fold 12 h after zafirlukast 
40 mg orally. This shift correlated with systemic 
exposure to zafirlukast. Sixteen of 20 patients who 
had dose-response shifts of IO-fold or greater had 
plasma concentrations greater than 5 ng ml ~ ’ at the 
end of the inhalation challenge. Nine of 13 subjects 
who had zafirlukast plasma levels of 5 ng ml - ’ or 
less had dose-response shifts of less than lo-fold (23). 
The plasma threshold for zafirlukast suggests a mech- 
anism of action requiring near-complete occupancy 
of the relevant LTD, receptors. SKB-104353 given by 
nebulization provides a lo-fold shift in the LTD, 
dose-response curve in normal subjects and asth- 
matics with protection for up to 4 h (24). MK-571 
displays >80-fold shifts when given intravenously in 
normal subjects and asthmatics (25). 
BIOSYNTHESIS INHIBITORS 
Zileuton at a single oral dose of 800 mg inhibits 
877100% of LTB, biosynthesis in whole blood (ex 
vivo) in volunteers for up to 6 h. However, incom- 
plete inhibition (-50%) of urinary LTE,, which 
reflects leukotriene biosynthesis in tissues, was 
observed. The authors concluded that more complete 
inhibition of 5-lipoxygenase in vivo may be needed to 
produce a clinical effect (26). Similarly, single oral 
doses (250-500 mg) of MK-886 inhibit leukotriene 
biosynthesis by only -5O%, with reductions in uri- 
nary LTE, excretion of -70% following oral doses 
of 115 mg t.i.d. for 10 days (27). 
EFFECT ON ALLERGEN-INDUCED ASTHMA 
A number of studies have investigated the inhibi- 
tory effects of anti-leukotriene intervention on acute 
early and late phase components of (inhaled) allergen 
challenge. Zafirlukast (100-200 pug) by the aerosol 
route inhibits the early, but not the late, response in 
the majority of ragweed-sensitive patients. Inhibition 
of ragweed-induced bronchoconstriction occurred in 
the absence of any improvement in FEV, (28). 
Zafirlukast (40 mg orally) 2 h before allergen chal- 
lenge has been shown to attenuate the early response 
by 80% and the late response by SO%, and partially 
prevented the associated increase in bronchial hyper- 
reactivity at 6 h after challenge in a group of atopic 
asthmatics (29) (Fig. 4). The effect on late phase 
bronchoconstriction was variable and only seen 
clearly in five of eight subjects. In contrast, in a 
further study in mild atopic patients, zafirlukast 
(inhaled doses up to 1600,~g) showed only a reduced 
early response with no effect on the late asthmatic 
response and no significant bronchodilator effect 
(30). The reason for the differences between the 
profiles of action of oral and inhaled zafirlukast are 
at present unclear. It may reflect differences not only 
in drug concentrations achieved in the lung, but also 
in the time that drug concentrations remain high 
enough to actually block LTD, receptors. A single 
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Fig. 4 Early and late phase responses after allergen chal- 
lenge. Six hour mean allergen-induced bronchoconstriction, 
expressed as percentage change in FEV, (mean + SEM) 
over time in atopic patients. Placebo (0) or zafirlukast 
40 mg (0) was given 2 h before allergen challenge. With 
permission from The Lancet. 
40 mg oral dose of zafirlukast has been shown to 
displace the allergen dose-response curve to inhaled 
cat allergen by a mean of lo-fold compared with 
placebo. Again, there was considerable inter-subject 
variability. Eight of 12 subjects required more 
allergen to provoke a bronchoprovocation response 
after dosing with zafirlukast than that required with 
placebo (range three-fold to 30-fold), three subjects 
demonstrated no difference (less than two-fold) and 
one subject required less allergen after zafirlukast 
(seven-fold less) (31). A lower 20 mg oral dose of 
zafirkulast, given 2 h before allergen challenge, pro- 
duced a shift in the dose-response curve correspond- 
ing to median dose increments of between 2.5 and 
55-fold (only seven of 10 patients were responders), 
and reduced the recovery time. The response to 
intradermal LTD, was inhibited, but there was no 
effect on the response to histamine (32). The reasons 
for the variability between subjects in the effect of 
leukotriene antagonism on the airway response to 
allergen challenge are unclear. One explanation may 
be that the 20 mg dose of zafirlukast is too low to 
provide significant antagonism of leukotrienes in all 
patients. However, in the study by Taylor et al., three 
of eight atopic patients were not protected by zafirlu- 
kast, even though the leukotriene antagonist was 
used at a higher dose of 40 mg orally. In view of the 
similar patterns of variability seen in these studies, it 
is again tempting to speculate that the variability in 
response to the active drug indicates patient hetero- 
geneity with respect to the relative importance 
of the leukotrienes for the asthmatic response. The 
immediate bronchoconstriction that follows allergen 
challenge in atopic subjects depends on the IgE- 
dependent release of various chemical mediators 
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Fig. 5 Airway inflammation after antigen challenge. 
Bronchoalveolar lavage fluid cell counts 48 h after antigen 
challenge (all doses). Zafirlukast 20 mg b.d. (solid bars), 
placebo (open bars). Source: Calhoun et al., 1995 (34). 
from activated inflammatory cells. It is evident that 
cysteinyl leukotrienes synergize with histamine as 
mediators of IgE-dependent contractions (33), and 
this may contribute to the early asthmatic response. 
The effect of zafirlukast (20 mg twice daily) on 
bronchoalveolar lavage (BAL) fluid and cell count 
has been investigated in a double-blind, placebo- 
controlled, two period cross-over study in 11 patients 
with mild asthma. After 5 days of treatment, segmen- 
tal antigen challenge was performed, followed by 
BAL 5 min and 48 h after challenge. There were no 
statistically significant differences in cell counts 
between zafirlukast and placebo 5 min after chal- 
lenge, but at 48 h, basophil and lymphocyte counts 
and histamine concentration were reduced by zafirlu- 
kast while eosinophil and macrophage numbers were 
unaffected (34) (Fig. 5). 
SKB-104353 has been shown to attenuate the early 
response to inhaled allergen (35) and MK-571 
(100 mg iv.) has shown an inhibitory effect of 88% 
on early and 63% on late responses to allergen (36). 
In normal subjects, the leukotriene antagonist 
zafirlukast, 40 mg orally, inhibits the bronchocon- 
striction induced by PAF by 59%, suggesting that 
PAF may induce the release of leukotrienes (37). 
Studies on allergen challenge with inhibitors of 
5-lipoxygenase have also demonstrated inter-subject 
variability. A single oral dose of zileuton 800 mg 
produced a small (25%) reduction in the immediate 
response to allergen, but had no effect on the late 
response (38). ABT-761 demonstrated protection 
against the early asthmatic response to inhaled dust 
mite (39). MK-866 (750 mg orally) in two doses 
inhibited the acute response to allergen moderately 
(mean 58%) and the late asthmatic response by a 
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Fig. 6 Exercise-induced bronchoconstriction. Exercise- 
induced bronchoconstriction 2 h post-dose of placebo (U) 
and zafirlukast 20 mg orally (O), expressed as a percentage 
of pre-exercise baseline FEV, (mean +C SEM) over 30mii. 
With permission from American Review of Respiratory 
mean of 44% (which was lost after 8 h) (40). These 
compounds had no effect on allergen-induced hista- 
mine responsiveness despite inhibition of LTB, 
biosynthesis by approximately 80% and of LTE, 
excretion by 50%. Maximum fall in FEV, during the 
acute response was inhibited by lo-51% by MK-866 
and during the late response by 17-65% (but was 
increased in three of eight subjects). 
EFFECT ON EXERCISE CHALLENGE AND COLD-AIR 
CHALLENGE 
About 80% of asthmatics show at least a 15% fall 
in peak expiratory flow after exercise. Exercise- 
induced bronchoconstriction (EIB) has been shown 
to be partially inhibited by leukotriene intervention. 
Zafirlukast appears to be the most potent leukotriene 
antagonist tested to date (19). Both inhaled and oral 
zafirlukast reduce bronchoconstriction induced by 
exercise challenge by 30-50% (Fig. 6). 
Protection afforded by zafirlukast was variable. 
Taken orally 2 h before exercise challenge, zafirlukast 
20 mg produced complete protection in three sub- 
jects, partial protection in four subjects and no 
protection in one subject (41). Inhaled zafirlukast 
400 pg 30 min before challenge produced complete, 
partial and no protection, each in one-third of 
patients (19). Similar results have been found with 
MK-571 160 mg, where although all subjects 
responded to treatment, the response was variable 
(35-100%) with only four of 12 subjects showing 
complete protection (20). SKB-104353 protected little 
if at all against the fall in FEV, after exercise 
challenge (20%) when compared with placebo (29%) 
although this was similar to the level of protection 
afforded by 20 mg disodium cromoglycate (42). 
Inhaled ICI-204219 also attenuated cold-air-induced 
bronchoconstriction in patients with mild to moder- 
ate asthma at 30 min post dose, an effect which was 
lost at 6 h and 24 h (43). 
Zileuton has been shown to attenuate the response 
of asthmatic patients to cold air by about 47% 
(44) and, more recently, ABT-761 has been shown 
to inhibit exercise-induced bronchoconstriction by 
61% (45). 
EFFECT ON ASPIRIN-INDUCED ASTHMA 
Approximately 2-5% of asthmatic patients are 
aspirin sensitive, developing bronchospasm, naso- 
ocular, gastrointestinal and/or dermal reactions 
following the ingestion of aspirin (46). The bron- 
chopulmonary reactions have been associated with 
urinary LTE, hypersecretion. The first study of 
leukotriene antagonists in aspirin-induced asthma 
reported approximately a 60% protection against 
oral challenge by inhaled SKB-104353 in five of six 
subjects, with no effect in one subject (47). A greater 
effect was found subsequently with MK-0679, and 
in eight aspirin-sensitive asthmatics, it displaced 
the aspirin dose-response curve ( -four-fold) and 
increased the dose of aspirin required to produce a 
20% fall in FEV,. The bronchodilator response lasted 
for at least 9 h but varied between 34 and 5%, and 
was found to correlate strongly with both severity of 
asthma and aspirin sensitivity (48). 
The 5-lipoxygenase inhibitor ZD-2138 has recently 
been shown to protect against aspirin-induced reduc- 
tion in FEV, by 15.4% (Fig. 7), an effect which was 
associated with 74% inhibition of the rise in urinary 
LTE, 6 h after challenge (49). The effect of these 
drugs in the day-to-day management of this type of 
asthma remains to be established. 
EFFECT ON AIRWAY TONE 
Leukotriene receptor antagonists do not improve 
airway tone in normal volunteers (22). In mild to 
moderate asthmatics, a single dose of 40 mg zafirlu- 
kast has showed a modest bronchodilator effect, 
increasing FEV, by a mean of 8% (Fig. 8). Broncho- 
dilatation was slow in onset (90 min) but sustained 
for at least 4 h (38). Improvement in FEV, from 
baseline in this lo-patient study varied between 
22 and 14%. The increase in FEV, persisted after 
nebulized salbutamol, suggesting that the broncho- 
dilator effect was additive. 
In contrast, in a further study in patients with 
moderate asthma, inhaled zafirlukast failed to pro- 
duce either significant bronchodilatation or an addi- 
tive effect with an inhaled &agonist (50). However, 
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Fig, 7 Aspirin-induced bronchoconstriction. Percentage 
change in FEV, (mean + SEM) over 6 h after aspirin chal- 
lenge. ZD2138 (0) or placebo (0) was administered 4 h 
before aspirin challenge. With permission from Thorax. 
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Fig, 8 Bronchodilator effect. FEV, (mean f SEM) over 4 h 
after zafirlukast 40 mg orally (0) or placebo (0) and after 
nebulized salbutamol. With permission from Tlze Lancei. 
an additive effect was found in a study with MK-571 
in 12 moderately severe asthmatics. In a double- 
blind, placebo-controlled trial, MK-571 increased 
airway calibre additively with salbutamol in addition 
to antagonising LTD,-induced bronchoconstriction. 
The degree of bronchodilatation correlated with the 
degree of baseline airway obstruction (51). More 
recently, a single dose of MK-0476 has been reported 
to produce a mean increase of 12% in IFEV, in 
patients with moderate asthma lasting up to 6 h (52). 
Two other leukotriene antagonists, L6-49923 and 
LY-171883, failed to improve airway function in 
asthma (3553). These results suggest that chronic 
production of cysteinyl leukotrienes may contribute 
to increased airway tone in asthma and the mainten- 
ance of baseline airflow obstruction, but that their 
importance varies in different patients. 
STEROID-SPARING EFFECT 
Two large double-blind, placebo-controlled, par- 
allel group studies have determined whether ad- 
dition of zafirlukast 20 mg twice daily could safely 
allow reduction of maintenance dosage of inhaled 
corticosteroids without jeopardizing control of 
asthma. 
In one study (54) patients with stable, mild asthma 
treated with 400-750 pg daily inhaled corticosteroids 
were randomized to 20 weeks of treatment (242 of 
359 patients received zafirlukast 20mg twice daily). 
In the second study (55) 262 patients using between 
500 and 2000 pug daily of inhaled corticosteroids were 
randomized to treatment using a 2: 1 ratio for zafirlu- 
kast over 12 weeks. The results of both studies were 
similar, showing a reduction in dose of corticosteroid 
in both active and placebo treatment groups without 
loss of control of asthma. The difference between 
treatment groups did not reach statistical significance 
and groups did not differ as regards daytime symp- 
toms, daily /&-agonist use or morning peak flow at 
the end of the studies. No beneficial effect of zafirlu- 
kast in reducing inhaled corticosteroid use was 
shown. The authors concluded that the design of the 
studies was not capable of demonstrating a difference 
in steroid sparing between zafirlukast and placebo. 
CLINICAL TRIALS IN CHRONIC ASTHMA 
Large clinical trials with leukotriene antagonists 
and synthesis inhibitors are very few, with little or 
no comparative data. Recently, a 13-week dose- 
response study in symptomatic patients with mild-to- 
moderate asthma suggested that increasing oral doses 
of zafirlukast show a trend for decreasing morning 
asthma symptoms and relief bronchodilator use, and 
for increasing morning peak expiratory flow rate. A 
statistically significant effect was achieved only with 
zafirlukast at a dose of 80 mg twice daily. The 
patients had previously been treated with &agonists 
alone, and there were a number of patient with- 
drawals in both the active and placebo groups due 
mainly to worsening asthma, adverse events and 
non-compliance (56). A further 13-week trial with 
zafirlukast 20 mg twice daily in mild to moderate 
symptomatic patients demonstrated significantly 
improved symptoms and lung function compared 
with placebo (57). 
Zafirlukast (20 mg orally twice daily) has been 
shown to have a measurable effect within 3 to 14 days 
of therapy with the improvements in morning peak 
flow seen at Day 14, representing 56% of the total 
change seen at Week 13 (58). In a 6-week study of 
zafirlukast (5, 10 or 20 mg twice daily) in symp- 
tomatic patients with moderate asthma, a linear 
582 Topical Review 
response to increasing doses of the antagonist found 
that only the 20 mg twice daily dose significantly 
decreased night-time awakenings (46%) relief bron- 
chodilator use (30%) and daytime symptoms (26%). 
FEV, increased by a mean of 11%. Patients who 
had been treated previously with &agonists alone 
demonstrated the greatest improvement in FEV,, 
compared with patients withdrawn from previous 
theophylline therapy (15 vs. 9%) (59). A further study 
of zafirlukast reported no improvement in night-time 
awakenings or evening peak flow throughout the 
13-week study period (58). 
The 5-lipoxygenase inhibitor, zileuton has been 
evaluated recently in 139 mild to moderate asth- 
matics not receiving oral or inhaled corticosteroids. 
At the highest dose of 2.4 g daily, there was a 15% 
improvement in baseline FEV, within 1 h of admin- 
istration, maintained at Week 4 (improvement of 
13.4%). Furthermore, zileuton reduced broncho- 
dilator usage and symptoms significantly compared 
with placebo (60). Interestingly, the bronchodilata- 
tion attained during the first 2 h after zileuton was 
about 40% of that which could be achieved by the 
inhaled &-agonist, salbutamol. This bronchodilata- 
tion is less than that seen with oral or high-dose 
inhaled steroids (61). Further, in a study in moderate 
asthma, zileuton improved symptoms and lung func- 
tion, and reduced the use of steroid rescue medication 
(62) and the FLAP antagonist MK-051 improved 
FEV, by 7% and reduced bronchodilator usage in 
a 4-week study of patients with moderate asthma 
taking inhaled corticosteroids (64). 
It would be of interest to investigate the full effect 
of leukotriene antagonism or direct synthesis inhibi- 
tion in symptomatic patients already controlled on 
inhaled corticosteroid therapy by analogy with a 
study using the long-acting ,&-agonist, salmeterol 
(62). 
COMPARATIVE STUDIES 
Few comparator studies have been reported to 
date. The effect of zafirlukast compared with sodium 
cromoglycate (SCG) was examined in 287 self- 
assessed mild to moderate patients. There were no 
consistent differences in efficacy between zafirlukast 
20 mg twice daily and SCG 1600,ug daily; both 
reducing symptom scores and improving lung func- 
tion compared with placebo at 13 weeks (65). Two 
studies with zileuton have incorporated active 
controls - namely theophylline and beclomethasone 
dipropionate. In a 14-week, 300-patient study, 
zileuton 400 mg and 600 mg four times daily was 
reported to show less efficacy than low-dose beclo- 
methasone dipropionate (400,~g daily) (66). A 
double-blind parallel comparison of theophylline and 
zileuton 1600 mg and 2400 mg daily in 377 patients 
with moderate asthma showed an improvement from 
baseline in FEV, values of 23.2, 22.0 and 21.2% 
respectively at Day 36 which was maintained 
throughout the 13 weeks of the trial. Corticosteroid 
rescue medication was required on at least one 
occasion during the study in 14.5, 10.9 and 10.4% 
of patients, respectively (67). 
SAFETY PROFILE 
In general, leukotriene receptor antagonists and 
synthesis inhibitors were well tolerated in the studies. 
Mild adverse events including headaches and 
gastrointestinal disturbances have been reported. 
Patients taking zafirlukast have also reported 
pharyngitis (65), and drug interaction data, specifi- 
cally with the anti-histamine terfenadine, is being 
investigated (68). However, patients taking zileuton 
have also reported dyspepsia, and laboratory findings 
indicate elevated values for liver enzymes, usually in 
the first 3 months of treatment with a quarter of these 
at eight-fold the normal value. To date, the incidence 
of drug-induced hepatitis with zileuton is 3% (66). 
The Food and Drug Administration Advisory Panel 
has recommended that zileuton carries a warning 
requiring specific 2-weekly monitoring of liver 
enzymes during the first year of therapy. 
Discussion 
The evidence presented supports the hypothesis 
that cysteinyl leukotrienes have a role in the patho- 
genesis of asthma, and that modulation of their 
production or action may have therapeutic implica- 
tions. However, it is also apparent that there is a wide 
degree of patient variability in response to leuko- 
triene intervention. Closer analysis of individual data 
from the majority of studies shows that patients 
could be categorized as complete responders, partial 
responders or non-responders. Moreover, patients 
with clinically indistinguishable forms of asthma may 
have biochemically heterogeneous disease, with 
different contributions from a variety of chemical 
mediators. A rational approach would suggest that 
leukotrienes are one group of mediators involved in a 
complex inflammatory process leading to the clinical 
manifestations of asthma. The natural comparison is 
with the anti-histamines or with PAF antagonists 
which have so far shown disappointing results in the 
treatment of asthma (69). 
To date, the leukotriene antagonists appear to be 
more efficacious than either 5-lipoxygenase or FLAP 
inhibitors. On the one hand, this is surprising since 
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enzyme inhibitors will remove not only cysteinyl 
leukotrienes, but also LTB, and 5-HETE production 
which have pro-inflammatory activity, whereas 
leukotriene antagonists are specific for LTD,, LTC, 
and LTE,. The enzyme inhibitors, however, have 
only been partially effective in inhibiting leukotriene 
biosynthesis in man. It is likely that it will be neces- 
sary to maintain 190% inhibition on a 24 h basis for 
such drugs to achieve their full potential. 
Early leukotriene antagonists had no significant 
bronchodilator activity, their effects being largely 
‘anti-bronchoconstrictor’ in nature. With the devel- 
opment of more potent compounds, there have been 
a number of reports of changes in small and large 
airway calibre, although the effects are generally 
small (- 10%). The degree of bronchodilatation 
afforded in the different studies varies, probably as a 
result of patient selection. The study of MK-571 was 
carried out in mild asthmatics taking bronchodilators 
alone (51) in contrast to the zafirlukast study in mild 
to moderate asthmatics, nine out of 10 of whom were 
taking inhaled corticosteroids, where the broncho- 
dilatation response was less (38). Interestingly, the 
bronchodilator effect with leukotriene antagonists 
is seen in asthmatics but not in normal subjects. Since 
the leukotriene antagonists lack non-specific bron- 
chodilator activity, this suggests that endogenous 
leukotriene production occurs in asthmatic airways, 
probably reflecting the underlying inflammation, pro- 
ducing some degree of tonic bronchoconstriction. 
Studies to date have shown that leukotriene antag- 
onists block only -50% of the late asthmatic 
response to allergen. It is not clear whether an even 
more potent leukotriene antagonist or one with a 
longer duration of action would have a greater effect, 
or whether mechanisms such as oedema formation 
and cellular infiltration involving other mediators are 
responsible for the residual airway narrowing. A 
rather unexpected observation was the attenuated 
increase in bronchial hyper-responsiveness by zafirlu- 
kast (29). This may be a genuine protective effect of 
a leukotriene antagonist against airways hyper- 
responsiveness, or may be the result of the baseline 
airway function in the actively-treated group being 
higher than the placebo arm in this study. The 
non-bronchodilator effects of the leukotriene antag- 
onists resemble those of long-acting inhaled 
&-agonists. Both groups of drugs affect the late and 
the acute responses to allergen challenge. This may 
be explained by long-lasting functional ‘antagonism’ 
with the &agonists, whereas the effects of the leuko- 
triene antagonists are mediator specific. Recent 
asthma management guidelines have stressed the 
importance of anti-inflammatory therapy even in the 
mildest forms of asthma. Further clinical studies are 
needed to clarify the exact role of leukotriene modu- 
lation in the treatment of asthma. Studies comparing 
leukotriene antagonists or synthesis inhibitors with, 
and in combination with, existing agents are awaited. 
Further antigen challenge studies are required in 
which patients with decreases in urinary leukotrienes 
also show improved lung function. Ultimately, until 
there is a clear demonstration of activity against 
eosinophil inflammation, these compounds cannot be 
classed as ‘anti-inflammatory’ but rather as mediator 
antagonists and enzyme inhibitors. The long-term 
effects of leukotriene modulators will have to be 
evaluated as the data from on-going studies becomes 
known. 
POSITION IN MANAGEMENT GUIDELINES 
Recently, the management of asthma has changed 
substantially, and new National and International 
Guidelines now recommend a stepwise approach 
to treatment, with the early introduction of anti- 
inflammatory treatment rather than reliance on 
short-acting bronchodilators. 
At Step 1 of the British Thoracic Society Guide- 
lines, the occasional use of short-acting &agonists, 
such as salbutamol or terbutaline, ‘as required’ to 
relieve acute symptoms is acceptable. If they are 
needed more than once daily, regular inhaled anti- 
inflammatory agents are indicated at Step 2. Gluco- 
corticosteroids are by far the most effective and most 
commonly used anti-inflammatory agents available, 
and are well tolerated when inhaled. The mode of 
action of these compounds is complex, but the 
multiplicity of anti-inflammatory actions of cortico- 
steroids probably accounts for their efficacy. Evidence 
for the anti-inflammatory actions of corticosteroids 
comes from studies of both bronchial biopsies and 
bronchoalveolar lavage fluid. To date, such evidence 
is not available for leukotriene antagonists and bio- 
synthesis inhibitors, and it is unlikely that they will 
replace corticosteroids in the treatment of chronic 
asthma. Corticosteroids have further proven efficacy 
in childhood asthma (70). At Step 3 in the Guide- 
lines, the inhaled corticosteroid dose may be 
increased if symptoms are not controlled adequately 
and compliance appears to be satisfactory. An alter- 
native at this step is the introduction of long-acting 
bronchodilators as an alternative to increasing the 
dose of inhaled corticosteroids. 
Early evidence indicates that leukotriene antagon- 
ists and synthesis inhibitors are likely to be effective 
in some patients with specific forms of asthma. For 
example, some patients with aspirin sensitivity may 
benefit. Drugs such as SCG and nedocromil sodium 
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are also of proven efficacy in mild asthma, but it is 
not clear how leukotriene antagonists and synthesis 
inhibitors will compare. 
More large ‘real world’ comparator studies are 
required to enable positioning of these drugs within 
revised management guidelines. 
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